For Eye Care Professionals
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial of NOV03 (Perfluorohexyloctane) in Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving its Surgical Technologies at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgery
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03 (perfluorohexyloctane)
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues to Reduce the Risk of Moderate to Advanced Age-Related Macular Degeneration Progression
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
Bausch + Lomb Announces Statistically Significant Topline Results from the First Phase 3 Trial of Nov03 (Perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device (OVD)
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
Bausch + Lomb Announces Scientific Data on Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses to be Presented at the Virtual Global Specialty Lens Symposium
Bausch + Lomb Completes Enrollment of First Phase 3 Study For NOV03 (perfluorohexyloctane)
Bausch Health Initiates Second Phase 3 Study for NOV03 Investigational Treatment for Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through ONE by ONE Recycling Program
Bausch + Lomb Highlights Surgical, Pharmaceutical and Consumer Health Care Innovations and New Business Ventures; Offers Educational Opportunities During The Annual Meeting of The American Academy of Ophthalmology